ArticleFrontiers in digital health2026
Prediction of maturity-onset diabetes of the young subtypes using machine learning.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Maturity-onset diabetes of the young (MODY) is a monogenic type of diabetes caused by different pathogenic genetic variants in glucose metabolism-related genes, with GCK-MODY and HFN1A-MODY subtypes being the most frequent. Diagnosing the specific MODY subtype is essential for correct treatment and follow-up, but it requires gene sequencing, a time-consuming and costly process that depends on highly skilled professionals. Therefore, it is mandatory to develop tools that allow to correctly determine in which order to study the involved genes, reducing the number of sequencing procedures to find the causal variant and making the diagnostic process more efficient. This proof-of-concept study evaluates machine learning as a complement to clinical characterization and genetic testing, by optimizing binary classification models for explainable prediction of MODY subtypes, with a focus on GCK-MODY and HFN1A-MODY. Methods: To meet this aim, we analyzed medical data from a diabetes cohort from Buenos Aires, Argentina. By employing imputation and oversampling techniques we created 10 datasets for each subtype to feed a pipeline that trained, optimized and evaluated 10 machine learning techniques. Results: Gaussian Naive Bayes achieved the best predictive power for GCK-MODY with a ROC AUC score of 0.724, meanwhile Random Forest yielded 0.712 for HNF1A-MODY. SHAP analysis provided insights into feature importance, highlighting the explainability of our approach. Discussion and conclusion: This novel study demonstrates for the first time the viability of machine learning as a supplementary tool prior to MODY genetic testing, by providing cost-effective and explainable models able to assist health professionals in the diagnosis of MODY subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.